Spinal muscular atrophy (SMA) is a rare genetic neurodegenerative disorder characterized by the loss of motor neurons, atrophy of the voluntary muscles of the limbs and trunk and progressive muscle weakness. It is typically fatal and is commonly diagnosed in young children. Biogen's Spinraza, Novartis' Zolgensma, and Roche's Evrysdi are some of the approved therapies for SMA.
The company we are profiling today is Biohaven Ltd. (BHVN), a global clinical-stage biopharmaceutical company, approaching a significant milestone in the coming months related to its spinal muscular atrophy (SMA) trial.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.